abstract | Rapid technical advances in DNA sequencing and genome-wide association studies are driving the discovery of the germline and somatic mutations that are present in different cancers. Mutations in genes involved in cellular signaling are common, and often shared by tumors that arise in distinct anatomical locations. Here we review the most important molecular changes in different cancers from the perspective of what should be analyzed on a routine basis in the clinic. The paradigms are EGFR mutations in adenocarcinoma of the lung that can be treated with gefitinib, KRAS mutations in colon cancer with respect to treatment with EGFR antibodies, and the use of gene-expression analysis for ER-positive, node-negative breast cancer patients with respect to chemotherapy options. Several other examples in both solid and hematological cancers are also provided. We focus on how disease subtypes can influence therapy and discuss the implications of the impending molecular diagnostic revolution from the point of view of the patients, clinicians, and the diagnostic and pharmaceutical companies. This paradigm shift is occurring first in cancer patient management and is likely to promote the application of these technologies to other diseases.
Introduction a large paradigm shift is occurring in cancer patient management, which may be realized before 2020 when molecular-based patient profiles will become part of routine diagnosis (Box 1, table 1). the molecular analysis of human tumors has allowed the development of new drugs that are directed at specific targets; examples include the tyrosine kinase inhibitor imatinib, and the monoclonal antibody trastuzumab. the molecular technologies that have been developed in the past 5 years, especially next-generation Dna sequencing, are dramatically improving our understanding of the genomic aberrations that underlie the malignant transformation of normal cells. these changes include coding mutations, changes in the sequence of promoters and enhancers, insertions and deletions in Dna, copy number variations, and chromosomal translocations. Pharmaceutical companies are developing drugs to target the changes that drive cancer cell proliferation and survival, and are trying to identify which tumors will respond to particular treatments. this strategy should give patients a better outcome and a more accurate view of their prognosis. this approach is being referred to as personalized medicine, where patients who are genetically similar and have the same disease at the molecular level, should respond to certain treatments in the same way.
Cancers that occur within a given tissue have distinct genomic changes that define each individual tumor in terms of the molecular mechanisms involved. the growth and survival of some cancer cells depends strongly on the activation of a single oncogene, a pheno menon that has been referred to as oncogene addiction. 1 Knowledge of the molecular defects that lead to cancer is providing a new way of classifying tumors based on molecular biology.
2 these objective molecular classifications, which include fluorescence in situ hybridization (FisH), complement the more subjective, observational techniques that have been traditionally used by patho logists, including tissue staining with hematoxylin and immunohistochemistry. these newer approaches are also making it easier to standardize molecular tests so that identical results can be obtained between individual laboratories. 3 some of the technologies and insights that are leading to a greater understanding of the molecular drivers behind cancer development and progression, and how this knowledge will affect patients, clinicians and pharmaceutical companies, are the subject of this review. the national Human Genome research institute, and the CosmiC (Catalogue of somatic mutations in Cancer) project supported by the wellcome trust, are illustrative of what will be achieved on a very large scale in the next few years through comprehensive genome sequencing. 5 as the price of Dna sequencing falls, it will inevitably replace older technologies, such as transcriptional profiling that uses oligonucleotide arrays to examine gene expression, and the use of large-scale single nucleotide polymorphism arrays to detect deletions and amplifications in tumors. some of this sequencing momentum is coming from the "$1,000 genome"-a technical challenge aimed at publicly funded laboratories and companies to develop technology that will allow the human genome
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The implications of the molecular pathology revolution are profound for both the ■ cancer patient and the health care system to be sequenced for $1,000. this project is related to the "1,000 genomes" project that aspires to sequence 1,000 genomes as cost effectively as possible, to provide a comprehensive catalog of all the common variants in the genome. 6 Both of these projects offer technology focus, but there is an additional (often overlooked) high cost to convert raw sequence data into useful information, especially if the information will be used to drive clinical decision-making. there is also an increasing need to put the genetic information into the right biological context. very few whole tumor genome sequences generated by second-generation Dna sequencing have been published. 7 although sequencing studies of tumor genomes provide useful information, particularly about mutation mechanisms, they also highlight the technical and data-handling issues that remain (Box 2). [8] [9] [10] third-generation systems, such as the Heliscope ™ platform (Helicos, Cambridge, ma, usa), smrt ™ Dna sequencing (Pacific Biosciences, menlo Park, Ca, usa), sequencing from Complete Genomics (mountain view, Ca, usa) and nanopore sequencing (oxford nanopore technologies, oxford, uK), are clearly being developed with clinical utility in mind. 11 Determining the suitability of such sequencing for diagnostic applications is important. one of the prevailing issues is whether to sequence the genomic Dna from a patient and tumor and sort the information of interest from the large pool of data, or instead, only sequence the regions of interest. 5 several selection systems for isolating defined regions of the genome are now available, including those from agilent (santa Clara, Ca, usa) and roche nimbleGen (madison, wi, usa), and others are being developed. 12, 13 these systems can select different types of Dna for analy sis, including exons, regions of genetic association, and different types of rna, such as transcribed regions via complementary Dna (cDna), microrna (mirna), and other small rnas of interest. targeted capture by hybridization of 12 human exomes (the complete set of exons), has been used to generate >300 megabases of coding regions to identify common and rare variants in the genome, including a gene involved in a dominant inherited disorder.
14 this approach is also being used to find rare mutations that predispose to cancer. the other major technology driver for cancer screening is genome-wide association studies (Gwas). Development of the Hapmap project that compares the genetic sequences of different individuals to identify chromosomal regions where genetic variants are shared, and access to relatively cheap chip-based methods to analyze single nucleotide polymorphisms across the human genome, has led to the publication of many Gwas in cancer and other diseases. 15 the utility of such studies has been called into question by some, 16 owing to the fact that only a small proportion of the overall genetic risk is being examined in these studies, but as far as cancer is concerned, Gwas have led to novel insights into the biology of the disease. 17 they have, however, yet to show any utility for cancer screening, largely because the associations are in common alleles and each on its own confers very small additional risk of The year is 2020. I wake up and feel the lump under my arm that has been bothering me for several weeks. I decide to make an appointment with the doctor to find the cause, especially since my personal genetic analysis has highlighted alleles that are associated with an increased risk of cancer.
The doctor's receptionist views my electronic health record online before I am buzzed in to see the doctor. Once I have explained the problem, a biopsy from the offending lymph-node is taken, the tissue is flash-frozen using the nitrogen quick-freeze system, and then delivered to the laboratory downstairs for a rapid molecular work-up.
DNA from the tissue is sequenced to identify any mutations in the 500 mostcommon genes known to be involved in cancer. Tissue sections are analyzed using high-resolution fluorescent optical images. A blood sample is also taken to check my background genomic DNA sequence, concentrating on alleles known to predispose to lymphoma. Sequences for the genes encoding drug-metabolizing enzymes and drug-distribution proteins are also obtained.
A proteomic work-up is undertaken to look at protein profiles and posttranslational modifications. I also undergo new-generation imaging so the gross pathology of my organs can be viewed in three-dimensions. Two hours later, I review the results on my handheld computer device. The results have been predigested and presented as a simple digital read-out so that a diagnosis, prognosis and appropriate treatment can be derived.
Fortunately, the overall molecular and cellular pathology of the lymph-node is considered normal. Apart from my pre-existing heart disease, all other organs appear to be healthy and I am prescribed an anti-inflammatory drug.
I leave the doctor's office with a sigh of relief that all appears to be well.
Reviews disease. 18 Combinations of low-risk alleles might have much greater impact, as suggested by analysis of cancer susceptibility genes in mice, but these combinations will be hard to identify and validate. By contrast, no one would question the utility of screening at-risk individuals for mutations in genes known to confer a much higher increase in relative risk of cancer predisposition. 19 one of the best examples of this approach is measuring mutations in BRCA1 and BRCA2, which confer a considerable increase in the risk of breast and ovarian cancer in women with mutations in one or the other of these genes, and different alleles of BRCA1 and BRCA2 have different predisposing effects. 20 the common alleles conferring low risk that have been identified by Gwas have not yet been linked to outcome (only susceptibility), and they do not account for all of the genetic risk of the cancers in question. 21 Consequently, it is thought that there are as yet undiscovered mutations in rare alleles of certain genes that confer the additional risk. the potential for sequencing Dna using next-generation sequencing to look for rare mutant alleles is alluring and will probably lead to the identification of genes that can be of diagnostic utility.
14 alternatively, there are likely to be more common genes that confer even smaller additional risks that may be found by Gwas in larger cohorts of patients and in populations where the allele frequencies are different. 22 two other related technologies that are driving the molecular understanding of cancer and that have therapeutic implications, are the use of mirnas and short hairpin rnas (shrnas). Developing mirnas as therapeutic or diagnostic entities may be important in the future, but their utility in uncovering genes involved in cancer is already proven. 23 several loss-of-function rna interference screens have been carried out, where genes involved in the proliferation and survival of cancer cells have been identified. using retroviral vectors, shrnas are delivered to tumor cells. shrnas that knock down a gene required for continued cell growth are eliminated from the overall shrna population after a series of cell replications; these rnas (and hence their targets) can then be identified by scanning for a bar code tag attached to the individual shrnas. in diffuse large B-cell lymphoma (DlBCl), this type of screen identified CARD11, a gene involved in nuclear factor kappa B (nFκB) signaling. 24 this approach has since been extended to investigate mechanisms of resistance of DlBCl cells to iκB (inhibitor of nFκB kinase subunit) inhibition by smallmolecule inhibitors. 25 a larger version of this approach has also been applied to leukemic cells from patients. mutations were not only found in known genes, such as JAK2 and KRAS, but also in several genes not identified before in this disease. 26 Pathways not previously linked to KRAS have also been found using rna interference-driven synthetic lethal screens. [27] [28] [29] [30] the results suggest several novel points of intervention by targeting genes that do not necessarily acquire mutations themselves to drive proliferation, but are important components of the malignant process.
Lung cancer
advanced non-small-cell lung cancer (nsClC) is the leading cause of cancer-related death in the world. it has a particularly poor prognosis that has changed little over the past 30 years, despite a greater understanding of the molecular and cellular biology of the disease. 31 as in other cancers, large genome scans have been carried out to identify associated susceptibility loci; a repro ducible region on chromosome 15q24-25.1 has been found. this region contains two genes coding for subunits of the nicotinic acetylcholine receptor, but whether these are of biological importance remains to be seen. [32] [33] [34] several studies have attempted to correlate geneexpression signatures with patient survival or tumor proliferation in different forms of lung cancer. in past studies, limited numbers of samples were assessed, and signatures involving small numbers of genes were identified as correlating with relapse or survival. the most comprehensive study so far collected 442 lung cancer samples from six clinical centers using the same method to provide consistency. 35 a training set was established first and the results were verified in additional independent data sets. the study was particularly focused on prognosis and survival time. a gene constellation that included cell cycle-related Reviews genes, was associated with poor outcome, and genes involved in a more differentiated cell phenotype correlated with better outcome. this study has set the scene for additional large studies looking at treatment modalities, gene-expression profiles, and outcomes. 36 attempts have also been made to assess the correlation of outcome and relapse with mirna expression levels in lung cancer. 37, 38 a major advance in the treatment of lung cancer was the finding that activating mutations or amplifications of EGFR were common in asian females with adenocarcinoma of the lung who had never smoked. these cancers were particularly responsive to EGFR inhibitors, such as gefitinib and erlotinib. more than 80% of these mutations are either point mutations in exon 21 (for example, l858r) or exon 19 deletions. 39 identifying EGFR mutations in all patients with lung cancer (whether smokers or not) will be important, as inhibition of this receptor has considerable clinical benefit. this observation was particularly evident in asian patients with EGFR mutations or amplifications treated with gefitinib in the iPass (iressa Pan asia study) trial. 40 in some trials, treatment of patients with inhibitors who do not have mutations in EGFR can worsen their outcome, and the inhibitors have less, if any effect in patients with KRAS mutations. in fact, the presence of KRAS mutations is a better predictor of response to gefitinib than the presence of EGFR mutations. the cancer cells eventually become drug resistant, however, either by accumulating additional mutations in EGFR (in particular the t790m mutation), or by compensatory mutations that activate other connected pathways to overcome the proliferative drive mediated by EGFR (Figure 1 ). these changes include MET amplifications, which correlate with poor outcome. 41, 42 Detection of EGFR mutations by examining lung cancer cells in the circulation or measurement of Dna mutations could become a convenient way to screen for these mutations during initial work-up and treatment. 43 the dramatic response to EGFR inhibitors in subsets of patients is a strong argument from a therapeutic perspective for attacking mutant oncoproteins with a cocktail of drugs. 44 studies of cDna from a retrovirus-mediated expression library have identified a fusion gene in nsClC cells derived from an inversion on chromosome 2p. the translocated gene fusion, EML4-ALK, is a transforming oncogene and was found in one study in approximately 6% of patients with nsClC. 45 novel isoforms of this translocated gene fusion have also been described. 46 this genetic change seems to be mutually exclusive to EGFR, KRAS or BRAF mutations, which suggests that routine measurement of this sequence abnormality should be done in clinical trials testing inhibitors of ALK. Quite remarkably, clinical data on the benefits of blocking ALK with PF-02341066 (Pfizer, nY, usa) were presented just 2 years after the EML4-ALK translocation was identified, and the compound has now entered phase iii clinical trials in patients with alterations in ALK. 47 Germline and somatic changes in ALK, including gene translocations, amplifications and mutations, are also found in ana plastic large cell lymphoma, neuroblastoma and inflammatory myofibroblastic tumors. 48 large-scale sequencing has confirmed and extended the number of somatic gene mutations found in lung cancer. the most frequently mutated tyrosine kinase genes include EGFR, ERBB4, and KDR (a veGF receptor) and several tumor suppressor genes, such as NF1, APC, RB1 and ATM. the tumor suppressor STK11 is also frequently deleted or mutated. 49 Germline alterations in STK11 are responsible for Peutz-Jeghers syndrome, and there is increasing interest in this gene owing to its role in controlling cell growth and metabolism via amPactivated protein kinase. 50 the amP kinase axis may be important both diagnostically and therapeutically, given the reliance of cancer cells on aerobic glycolysis (the warburg effect). 51 the fact that mutations in KRAS and EGFR in the same tumors are mutually exclusive has been confirmed by genome sequencing, and KRAS mutations were most often associated with tumors from smokers. 52 Certain genes, including PTEN (phosphatase and tensin homolog) and EGFR were mutated in tumors at lower than average mutation rates, suggesting that their activation was a sufficiently positive selection factor to reduce the accumulation of additional mutations. a comprehensive picture of the mutations in the genes in signaling pathways in lung adenocarcinoma is shown in Figure 2 . 52 in the same study, 17 genes in the mammalian target of rapamycin (mtor) pathway were mutated in >30% of the lung tumors sequenced (excluding those with KRAS mutations), indicating that sirolimus and other mtor inhibitors could be used in lung cancer patients with mutations in this pathway. 52 moreover, MEK inhibitors could be tested in tumors with NF1 mutations, and patients with KDR mutations could benefit from semiselective kinase inhibitors, such as sorafenib or sunitinib. whole genome sequencing of this kind will increasingly be used in lung cancer to direct attention to particular therapeutic targets.
Box 2 | Issues concerning the current genome sequences
The human genome sequence data is far from perfect; a good example is the region of chromosome 8q24, which is associated with susceptibility to several common types of cancer, including breast, ovarian, prostate, colorectal and bladder cancer. 156 This region has been sequenced and assembled in the original Human Genome Project, in the Celera assembly, and from the DNA sequences from defined individuals. There is also an available 'finished' sequence from chromosome 8 from the International Human Genome Sequencing Consortium.
Subsequently, a Chinese sequence 158 and data from the 1,000 genomes project have been added to the genome sequence databases.
159 Information is also available in this region through the analysis of bacterial artificial chromosome and fosmid ends spanning the region for eight additional individuals from the original sequencing projects and from a Korean individual's DNA sequence. 160 There are also traces at varying depths from individuals in the HapMap database and from sequencing centers, but it is still difficult to define a consensus-complete sequence across this region. This situation is likely to prevail for much of the rest of the genome sequence. Indeed, it has been necessary to carry out further sequencing to identify new single nucleotide polymorphisms for the more precise genetic mapping of the 8q24 region. 161 Further sequencing of parts of or all of many different human genomes will provide a catalog of the most common inherited variants, and properly finished genome sequences should be deposited in the appropriate databases. 162 
Reviews

Colorectal cancer (CRC)
Despite the classical molecular model of the development of CrC being described 20 years ago, histopathological examination of colorectal tumor biopsies and the degree of lymph-node involvement are the mainstay for the classification of CrC. increasingly, however, molecular markers are being used to further classify the disease. 53 High-risk hereditary genes include adenomatous polyposis coli (APC), which acts via β-catenin to control wnt gene-directed cellular signaling, and mutations in Dna mismatch repair genes (MLH1, MSH2, MSH6, and PMS2). testing for the mutation status of these genes is recommended in high-risk families where early onset disease is apparent. mutations in mismatch repair genes lead to the accumulation of mutations in other genes that are not repaired by the normal mechanisms and, thus, predispose to cellular proliferation. this repair process is especially important in the gut mucosa. Deletion of the long arm of chromosome 18q is a common cyto genetic abnormality in CrC and correlates with poor prog nosis. However, studies of the oncogenes in that location, such as SMAD4, have failed to show any reliable correlation with outcome. 54 Gwas have identified alleles on chromo somes 8q23, 8q24, and 10p14 that confer risk of disease. 55, 56 stratification of patients with CrC by using geneexpression signatures is in the process of being developed. Genomic Health announced in 2009 that their Quasar validation studies met their primary end point to predict the likelihood of recurrence for patients with stage ii colon cancer following surgery. they stated that the colon cancer recurrence score ® provided additional independent clinical value beyond standard measures of risk and that the test would be available in 2010. 57 other work describing a 50 gene expression set that accurately predicts recurrence in early stage CrC, has also been published, but the study did not examine a very large number of patients. 58 the chemotherapy regimens for metastatic CrC (FolFiri or FolFoX) consist of fluorouracil derivatives plus irinotecan, or oxaliplatin. the metabolism of 5-fluorouracil (an inhibitor of thymidylate synthetase) is mediated by polymorphisms in catabolic genes, such as dihydropyrimidine dehydrogenase. Genetic polymorphisms in uridine 5'-diphospho-glucuronosyl transferases that metabolize irinotecan are also clinically relevant in determining the risk of neutropenia, which occurs in some patients treated with this drug. 59 it is important to know whether patients treated with these drugs have mutations in these metabolic genes so that the dose can be titrated accordingly.
one of the most important discoveries for the clinical management of CrC is the association of mutations in KRAS and the efficacy of monoclonal antibodies targeting EGFR, such as panitumumab and cetuximab ( Figure 1 ). some tumors harbor somatic mutations in exon 2 of KRAS (codons 12 and 13) that compromise the hydrolysis of ras-bound GtP to GDP, resulting in constitutive activation of the ras pathway. KRAS mutations occur in approximately 40% of CrC. Data have shown that tumors with KRAS mutations do not respond to eGFr inhibition. 60 a european clinical trial failed to gain approval of panitumumab for treatment of late-stage colon cancer, and further analysis of the data showed that only those patients with tumors with wild-type KRAS responded to treatment. Despite lack of FDa approval, it is now accepted clinical practice to determine the KRAS status of all patients with advanced CrC. 61 Patients treated with FolFiri, anti-veGFr antibody (bevacizumab), and an anti-eGFr monoclonal antibody, fare worse if their tumors have KRAS mutations. 62 these studies have been extended to include other genes in the ras pathway: tumors with gain-of-function mutations in BRAF or PI3K, or loss of PTEN expression, also appear unresponsive to panitumumab and cetuximab. in the future, it is likely that only quadruple-positive patients (those who are wild-type for KRAS, BRAF, PI3K and PTEN), will be treated with these agents. 63 Breast cancer the two most important high-penetrance genes predisposing to breast cancer are BRCA1 and BRCA2. individuals with mutations in these genes have a 15-20-fold increase in risk of disease compared with the general population. BRCA1-related breast tumors are usually high-grade with early onset and are referred to as triplenegative cancers as they lack expression of estrogen receptor, progesterone receptor and Her2 (erBB2) receptors. BRCA1 and BRCA2 affect the capacity of cells to undergo homologous recombination and Dna repair. the prognosis of patients with breast (and ovarian) cancers that harbor BRCA1 and BRCA2 mutations is generally worse than those expressing hormone receptors. Genes that confer lower risk have been identified in some populations, the most notable of which is CHEK2. 19 also, germline mutations in PTEN are associated with florid bilateral fibrocystic breast disease and a substantially increased risk of breast cancer; mutations in CDH1 are associated with an approximate 40% risk of lobular breast cancer and diffuse gastric cancer.
Gwas have pinpointed other regions where common alleles that confer some additional relative risk of disease have been identified, including 2q35, 5p12 and 16q12. [64] [65] [66] alleles of FGFR2 (fibroblast growth factor receptor 2) have also been associated with additional risk of sporadic breast cancer, and a larger Gwas has identified additional genomic regions including 1p11.2, 3p24 and 17q23.2, and the RAD51L1 gene, to be associated with increased risk of breast cancer. [67] [68] [69] analysis of single nucleotide polymorphisms in the TP53 pathway revealed allelic variants at position 309 in the MDM2 promoter, which control the expression of this gene. individuals with one allele express higher levels of MDM2 compared with individuals who express the other allele. since mDm2 is a p53-specific e3 ubiquitin ligase that controls the degradation of p53, higher expression of this gene leads to lower levels of active p53. as a result, patients with increased MDM2 expression may be at increased risk for multiple types of cancer, including breast cancer and prostate cancer and may be less responsive to treatment owing to the lower levels of p53 present in their cells. 70 the relationship between breast cancer susceptibility genes and relative risk is shown in Figure 3 and demonstrates how the associations were found (family studies, resequencing, or Gwas), and indicates also the relative importance of measuring them in the course of patient management. 19 Developments in breast cancer treatment have shown that targeted therapies can have dramatic effects, but such therapies are only of benefit in a subset of patients and as a result, diagnostic assays are required. trastuzumab is a humanized monoclonal antibody directed to the cell surface tyrosine kinase receptor, Her2. early in the development of this drug it was observed that only tumors that overexpressed HER2 responded to treatment. overexpression of HER2 occurs in only about 20-25% of breast cancers. this information led to the co development of a diagnostic test, the Herceptest ™ (Dako, Glostrup, Denmark), which measures the level of Her2 by immuno histochemistry. FisH can also be used to detect HER2 amplifications. these technologies identify tumors with overexpression of HER2 and the patients who are, therefore, eligible for trastuzumab treatment. approximately 20% of patients who are treated with trastu zumab, however, are never tested for HER2 status.
Gene-expression profiling has identified at least four major breast cancer phenotypes: luminal a, luminal B, Her2-like, and basal-like. 71, 72 Both luminal a and luminal B subtypes are generally estrogen receptorpositive and, therefore, candidates for treatment with hormonal blockade with drugs, such as tamoxifen. the luminal B subtype has an increase in the expression of genes associ ated with cell proliferation. luminal B tumors have a poorer overall outcome than the luminal a subtype. 71, 72 Gene-expression profiling can provide information that enhances the prediction of clinical outcome compared with information obtained by tradi tional (table 2) . lowrisk patients would not receive chemotherapy whereas high-risk patients would. a limitation of these tests is their inability to subdivide er-negative or triple-negative patients into high or low-risk categories. 73 Prospective studies are underway (minDaCt and tailorx) to assess mammaPrint ® and oncotype DX ® , to provide information on the utility of these tests for the clinical management of breast cancer.
a key observation for the management of breast cancer patients is that breast cancer cells harboring mutations in BRCA1 or BRCA2 are profoundly sensitive to the new poly(aDP-ribose) polymerase (ParP) inhibitors. 74 several ParP inhibitors are now in clinical trials in breast cancer targeting triple-negative patients and patients with BRCA1 or BRCA2 mutations. an inhibitor of ParP has also been used in a phase 0 trial where profiling the patient is part of the trial process. 75 unfortunately, the number and size of the mutations in the BRCA1 locus, and the price of the testing may affect the ability to do this type of screening routinely to identify the right patients for clinical trials. 76 synthetic lethal screens using sirna are not only being used for cancer drug discovery, but also to find other cellular targets that are synthetically lethal in combination with ParP inhibitors. CDK5, a cyclin-dependent kinase that is abnormal in a small percentage of breast cancers, has been identified by this means. Patients with gene loss by 7q deletion or reduced CDK5 expression, and patients with BRCA mutations and Pten deletions may, therefore, also benefit from ParP inhibitors. [77] [78] [79] [80] tests that can predict response to chemotherapy are also needed. the efficacy of tamoxifen, which is metabolized to the active drug endoxifen by cytochrome P450 2D6 (CYP2D6), is compromised by a poor metabolizer phenotype as a result of inherited insufficiency of the enzyme owing to gene loss or mutation; efficacy is also reduced by the coadministration of drugs that are also metabolized by CYP2D6, including selective serotonin reuptake inhibitors. Genotype and phenotype-based CYP450 testing is available and should be used to determine the status of CYP2D6 and the potential consequences of drug-drug interactions in women eligible for tamoxifen treatment. 81 Prostate cancer measuring rising levels of prostate-specific antigen (Psa), followed by examination and a biopsy, is the current approach to diagnose prostate cancer. the widespread adoption of Psa screening has, however, led to a major shift towards the diagnosis of small, early-stage tumors, which has raised questions regarding their clinical importance. 82 the early detection of lesions that have no clinical consequence is a specific issue with respect to prostate cancer, but will become important for all cancers when molecular diagnostics are used more widely.
although there is a substantial familial risk for prostate cancer, it has been difficult to determine the underlying genetics of the disease. with the exception of BRCA2, which confers an increased risk for lifetime prostate cancer of >20-fold, there seem to be no other pre disposing genes of large effect. Gwas of prostate cancer have highlighted several regions of the genome that are associated with susceptibility to disease, such as 8q24, particularly in african americans. some of these alleles are also implicated in susceptibility to other solid tumors, including breast and colon cancer. 83 these low-risk susceptibility alleles account for approximately 20% of the familial risk of prostate cancer. these associated alleles are some distance from MYC on chromosome 8 and there is increasing evidence to indicate that these susceptibility regions operate by long-range control of MYC expression through enhancer or promoter interactions.
84-88 some evidence have not yet been identified. 19 Abbreviations: AKAP9, A-kinase anchor protein 9; ATM, ataxia telangiectasia mutated; BRCA1, breast cancer type 1 susceptibility protein; BRCA2, breast cancer type 2 susceptibility protein; BRIP1, Fanconi anemia group J protein; CASP8, caspase-8; CDH1, cadherin-1; CHEK2; serine/threonineprotein kinase Chk2; FGFR2, fibroblast growth factor receptor 2; LSP1, lymphocytespecific protein 1; MAP3K1, mitogen-activated protein kinase kinase kinase 1; PALB2, partner and localizer of BRCA2; PTEN, phosphatase and tensin homolog; STK11, serine/threonine-protein kinase 11. www.nature.com/nrclinonc also suggests that the effects of the 8q24 association interact with regions of cancer susceptibility on 17q. 89 a variant single nucleotide polymorphism in close proximity to MSMB (beta microseminal protein) on chromosome 10q11.2 has also been associated with prostate cancer.
90,91 the variant seems to be involved in the control of expression of MSMB, which is a potential candidate gene largely owing to the location of the expressed protein. 92 Gene fusions involving transcription factors have been found in prostate tumors. Fusions of the 5' untranslated region of TMPRSS2 (coding for a putative, uncharacterized serine protease) on chromosome 21 (21q22.3) have been identified by FisH in many late-stage tumors. TPMRSS2-ERG fusions, apparently caused by an internal deletion on chromosome 21, are associated with an androgenindependent, highly aggressive and lethal subtype of the disease. 93 absence of these fusions or PTEN loss correlates with a favorable outcome and a lower likelihood of disease recurrence. 94 whether this subtype would benefit from especially aggressive treatment early on remains to be seen, but examining TPMRSS2 fusions and PTEN status in prostate cancer will become important in the future. 95.96 it is surprising, given that prostate cancer is a common disease, that there is less understanding of the genetic basis of this cancer compared with other cancer types. 97 
Melanoma
Germline mutations in p16 and CDK4 were discovered over 10 years ago as major familial melanoma pre disposing genes. a third familial gene ( p14 ARF) is derived from an alternative reading frame of the CDKN2A gene locus. 98 some progress has been made in finding low-penetrance melanoma genes in families, and large Gwas have been carried out to identify loci conferring lower susceptibility. 99 Gene-expression signature studies have been done in melanoma, where one of the most important has led to the derivation of a protein-based test to measure the expression of five genes that can distinguish malignant melanoma from benign nevi. 100 other studies are being directed to correlate gene-expression signature with progression and outcome. the analysis of somatic mutations has been more informative. one example is an activating mutation of BRAF (v600e), which is found in most melanomas. a novel thera peutic agent (PlX4032) being developed by Plexxikon (Berkeley, Ca, usa) specifically targets this mutant form of BRAF and is currently in clinical trials. 101 other cancers, such as thyroid and lung cancer also harbor BRAF mutations. the BRAF gene is part of the mitogenic pathway downstream of KRAS and activating mutations in BRAF could, therefore, interfere with drugs acting upstream in the pathway, and suggests that PlX4032 may be useful for treating cancers other than melanoma. 102 since the drug specifically targets the mutant form of BRAF, it will be important to have a companion diagnostic test that can distinguish the BRAF v600e mutation from the wild-type gene. analysis of somatic mutations in tyrosine kinase genes in cutaneous melanoma identified recurrent mutations in ERBB4, which could lead to therapeutics directed specifically towards patients with tumors with mutations in this protein. 103 approximately 5-10% of melanomas also have mutations in KIT and respond dramatically to imati nib treatment. Distinguishing these patients from those with BRAF mutations, who do not respond to imatinib, is of considerable importance clinically. 104 
Pediatric solid tumors
the small round blue cell tumors, which include neuroblastoma, rhabdomyosarcoma, non-Hodgkin lymphoma, and ewing sarcoma, represent four of the most aggressive solid cancers in the pediatric population. accurate diagnosis is critical to the management of these patients; for example, patients with high-stage rhabdomyosarcoma require a combination of high-dose chemo therapy, surgery and radiation treatment, whereas patients with nonHodgkin lymphoma require intra thecal chemotherapy.
there is currently no single test to precisely distinguish these cancers. to confirm diagnosis, pathologists rely on several techniques, including immunohisto chemistry, cytogenetics, FisH and real-time PCr. molecular techniques to measure tumor-specific chromo some trans locations are used to diagnose ewing's sarcoma containing the EWS-FLI1 translocation, and alveolar rhabdo myo sarcoma containing the PAX3-FKHR translocation.
using microarray gene-expression profiling and artificial neural networks, 93 genes have been identified as a gene-expression signature that allow the stratification of these small round blue cell tumors to specific diag nostic categories. 105 measuring the expression of a subset of these genes is sufficient for stratification, making a realtime PCr-based test a possibility to allow the classification of these tumors. 105 upregulation of and mutations in the FGFR4 gene also seem to promote metastasis in rhabdo myosarcoma patients. in approximately 22% of all neuro blastoma tumors and is an independent predictor for poor prognosis. although this risk stratification accurately predicts that >80% patients with low risk, and <30% of patients with highrisk disease will survive with therapy, it cannot predict the outcome of indivi dual patients with neuroblastoma. Gwas in neuro blastoma have identified three commonly associated single nucleo tide polymorphisms at 6p22, and a subset of high-risk neuroblastoma patients also show associ ation on 2q35 to the BARD1 gene, which codes for a BrCa1-associated rinG domain 1 protein. 107 microarray studies have demonstrated that neuroblastoma tumors have a diagnostic-specific gene-expression profile compared with normal tissues or other malignancies. the gene-expression profile of low-stage tumors is also markedly different from those of high-stage tumors. [108] [109] [110] Furthermore, 19 genes including MYCN and CD44, had an expression profile that had a positive predictive value of >80% for poor outcome for patients with neuroblastoma of all stages. most of these 19 genes are involved in early neural development, suggesting that the more aggressive phenotype is characterized by less differentiated cells. other gene-expression studies have also correlated expression of gene sets with outcome for neuroblastoma (table 2) . 111, 112 in surveys of germline and somatic mutations in neuro blastoma, high-level amplification (>10 copies) and mutation of ALK (anaplastic lymphoma kinase) have been observed, especially in patients with advanced disease. 48, [113] [114] [115] this observation is interesting as ALK is deregulated in other cancers, for example, EML4-ALK in nsClC, as described above, and NPM-ALK in nonHodgkin lymphoma. 116 tyrosine kinase inhibitors that target ALK could, therefore, be useful in the clinical management of neuroblastomas with activated ALK. the MET tyrosine kinase inhibitor PF-02341066, which also inhibits ALK, is currently being tested in a phase i/ii trial for neuroblastoma patients (nCt00939770).
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Non-Hodgkin lymphoma
non-Hodgkin lymphomas account for approximately 5% of all cancers diagnosed in the us and the incidence is rising due to the increasingly ageing population. nonHodgkin lymphomas are classified as either t-cell or B-cell in origin and can be indolent or aggressive in character. seminal studies by the leukemia lymphoma molecular Profiling Program and the nCi in the past 10 years, have demonstrated the feasibility of using gene-expression microarray technology for the identification and classification of a variety of lymphoma sub-classes. Burkitt's lymphoma is an aggressive form of non-Hodgkin lymphoma associated with a translocation of the MYC gene (t [8;14] ) that can be difficult to diagnose using histopathology and can sometimes be confused with DlBCl. successful treatment of Burkitt's lymphoma requires a more aggressive chemotherapy regimen than DlBCl. accurate diagnosis and clear differentiation of Burkitt's lymphoma from DlBCl is critical to improve patient outcome. several studies have demonstrated that geneexpression arrays can be used to identify Burkitt's lymphoma in patients with disease diagnosed as DlBCl by histopathology. 117 in a separate study, a Burkitt's lymphoma signature was identified that showed decreased expression of genes in the nFκB pathway, and increased expression of genes that were targets of MYC. 118 a subset of high-grade Burkitt's lymphoma patients who had been treated with CHoP (cyclophosphamide, adriamycin, vincristine, and prednisolone), which is the standard of care for DlBCl, were identified by this means. these patients were shown to have inferior survival compared with patients treated with the more aggressive ePoCH therapy (etoposide, doxorubicin, vincristine, prednisolone, cyclophosphamide) and rituximab, an anti-CD20 antibody. 118 a diagnostic test based on these gene-expression differences has the opportunity to prolong the lives of Burkitt's lymphoma patients who are difficult to distinguish from DlBCl. 118 DlBCl has been considered to be a single, albeit hetero geneous disease, and is generally treated with CHoP therapy, sometimes given with rituximab. novel molecular gene-expression signatures have now also identified distinct biological subtypes of DlBCl: germinal center B-cell-like, activated B-cell-like, and primary mediastinal B cell lymphoma. these forms of lymphoma differ in both prognosis and use of the most appropriate therapy. the t [14;18] translocation involving BCL2 and amplification of the REL locus on chromosome 2p is seen exclusively in germinal center B-cell-like tumors. By contrast, the nFκB pathway is activated in activated B-cell-like cells but not germinal center B-cell-like cells. 119 the germinal center B-cell-like subtype responds well to traditional CHoP therapy, as well as CHoP plus rituximab, whereas the activated B-cell-like subtype has a generally poor prognosis and needs additional therapeutic approaches. new drugs targeting nFκB are being tested in this poor prognosis group. the proteasome inhibitor bortezomib, which inhibits the nFκB pathway, has been tested in conjunction with chemotherapy of relapsed and refractory DlBCl in a small phase ii clinical trial. the results showed differential efficacy of bortezomib in the DlBCl subtypes defined by gene-expression signature. 120 in addition to these subtypes, the microenvironment of the tumor cells is important, and gene-expression signatures have defined two distinct stromal subtypes. 121 the stromal signatures correlate with survival after CHoP plus rituximab treatment.
array technology and Dna sequencing have also been used to identify gene copy number changes and mutations in DlBCl. recurrent oncogenic mutations affecting the nFκB pathway have been identified, such as CARD11, a gene coding for a cytoplasmic scaffold protein involved in nFκB activation. 122 other studies have shown that there is frequent inactivation of TNFAIP3, a negative regu lator of nFκB in B-cell lymphomas, presumably of the activated B-cell-like type. 123, 124 all these studies demonstrate that the loss or activation of several genes promote cellular proliferation by activating nFκB. this evidence strongly suggests a benefit for using drugs directed at nFκB for DlBCl, 125 and it may also be appropriate to test the new NEDD8-activating enzyme inhibitors in molecularly profiled, activated B-cell-like patients with DlBCl. 126 
Chronic myelogenous leukemia (CML)
routine histopathology and cytogenetic analysis are commonly used for leukemia diagnosis, but molecular techniques are being used increasingly to refine the diagnosis and to subdivide patients. 127 Chronic myelogenous leukemia (Cml) is considered a prototype for personalized genetic medicine. the Philadelphia chromosome is a translocation between chromosome 9 and 22 (t [9;22] [q34;q11]) that is diagnostic of Cml. this chromosomal abnormality gives rise to BCR-ABL, which codes for a constitutively active BCr-aBl kinase and leads to uncontrolled cell proliferation. the aBl kinase is a target for the tyrosine kinase inhibitor imatinib. a trial of imatinib in Cml patients showed good efficacy and gained rapid approval for the treatment of Cml.
128 imatinib inhibits both Kit and PDGFr and is being used to treat gastrointestinal stromal tumors and other cancers where these enzymes are activated or overexpressed. in the chronic phase of Cml, imatinib works by binding to BCr-aBl kinase and prevents the production of progenitor cells involved in myeloid differentiation, although the compound does not inhibit fully differentiated cells. imatinib kills most progenitor cells that have uncontrolled Dna replication, but inevitably drug resistance occurs. Patients who develop resistance to imatinib are being treated with newer inhibitors, such as dasatinib and nilotinib. 129, 130 the t315i mutation in BCR-ABL is not inhibited effectively by any currently available compounds, leaving no viable treatment options for patients with imatinib-resistant Cml, although one study has described aP24534 as a potent BCr-aBl t315i inhibitor in preclinical models. 131 sequencing BCR-ABL in cells from patients with imatinib-resistant disease is becoming an important part of Cml patient management.
Despite being an excellent example of personalized medicine, Cml and the development of imatinib are unusual in several respects. First, cell proliferation is driven by changes in a single gene and second, imatinib was originally developed as a PDGFr inhibitor rather than targeted to BCr-aBl. nevertheless, imatinib has not only fundamentally changed the life expectancy of patients with Cml or gastrointestinal stromal tumors, it has also fully justified the development of an agent for a disease with an incidence of only 5,000 new cases a year, and a prevalence then of <20,000 patients. this achievement proves that targeted therapies can be successful both clinically and commercially. 135 although the analysis was based on single nucleotide poly morphisms and copy number variation rather than on sequencing, this study has confirmed the data derived by sequencing the genome of an individual with aml. 136 Both studies showed low-level changes in genes in pathways already implicated in this cancer, such as FLT3 and TP53. Follow-up data from different patients suggest that these mutations do not occur by chance. mutations in the IDH1 gene were also found in aml and could be of potential importance.
136,137 these were not the same mutations as those found in this gene in similar sequencing studies of gliomas (see supplementary material for discussion of mutations in glioma and other cancers).
Acute lymphoblastic leukemia the cure rate for acute lymphoblastic leukemia (all) using conventional chemotherapy is >80%; however, the prognosis is grim for those children who do relapse. Gene copy number analysis has been used in an attempt to dissect those genes involved in relapse and treatment response. the evidence points to changes in the copy number of genes involved in cell cycle regulation and B-cell development.
138,139 more than 50 copy number abnormalities were found in a cohort of 221 children with high-risk B-cell progenitor all. alteration of the IKZF1 gene, which encodes a lymphoid tissue transcription factor (iKaros) was a predictor of poor outcome. the gene-expression signature of patients with poor outcome showed increased expression of hematopoietic stem cell genes and reduced expression of genes of the B-cell lineage. these signatures were similar to those obtained for BCR-ABL-positive all, a high-risk group with a high frequency of IKZF1 deletions and probably related to activating mutations in the Janus kinases. 140 Further studies should make it possible to identify those children who are more likely to relapse, and identify the most effective treatment modalities. a Gwas in all also showed association of the IKZF1 gene with susceptibility to disease, and reported two other regions of interest, both of which involve transcriptional regulation of genes in the B-cell progenitor lineage. 141 approximately one-third of patients with myelodysplastic syndromes and myeloproliferative disorders progress to aml. myeloproliferative disorders, such as polycythemia vera frequently present with a somatic activating mutation in the Janus kinase gene JAK2 (v617F). 142 mutations in a candidate tumor suppressor gene (TET2) have also been described in approximately 15% of patients with various myeloid cancers and are thought to arise before the JAK2 mutations.
143 while the precise role of JAK2 mutations in these diseases is not completely clear, several JaK2 inhibitors have shown signs of activity in early clinical trials in all. 144 
Chronic lymphoblastic leukemia
Chronic lymphoblastic leukemia (Cll) is the most common human leukemia. it is generally indolent in character, but incurable. the expression of nonmutated versions of the immunoglobulin heavy chain variable region locus, and leukemic cell expression of CD38, is associated with more-aggressive forms of the disease. the expression of ZAP70, an intracellular tyrosine kinase associated with t-cell signaling, is a marker of un mutated immunoglobulin heavy chain variable region and thus a biomarker for less indolent disease. 145 Patients with ZaP70-positive Cll cells should be monitored closely, as they require chemotherapy sooner than patients with more indolent forms of this disease. 146 two mirnas have been identified as tumor suppressors controlling the pathogenenesis of Cll. Both mirna 15a and mirna-16-1 are found in a region of chromosome 13 (13q14) that is frequently deleted in Cll cells. these studies were the first to show that mirnas are involved in the pathogenesis of a human tumor; subsequent studies have shown the importance of mirna-controlled gene expression in other cancers. 147, 148 Conclusions the understanding of the underlying germline and somatic mutations involved in cancer (supplementary tables 1 and 2) is already allowing earlier diagnosis and more appropriate treatment for patients (Box 3). although this understanding will not necessarily lead to a cure for cancer, the ability to diagnose and treat more effectively using drugs directed to the molecular defects that are present in particular tumors, will change the clinical management of cancer into that of managing a more chronic disease state. many of the large cancer centers are already triaging patients with different types of cancer for the routine analysis of biopsies to identify gene mutations. 149 Gene-directed clinical trials will be carried out in nsClC patients who are segregated by having mutations in KRAS, EGFR or ALK, or other genes in their tumors. in breast cancer patients, Pi3K inhibitors could be used in cancers that have failed trastuzumab and have PI3K mutations or HER2 amplifications, although the combination of the mutations and the selectivity of the inhibitors are going to be complex even for compounds targeting just one pathway. 150, 151 several issues could hinder delivery of genetic information to the patient. First, research findings with clinical material are often not translated into the clinic. For example, the expression profiling that has been done for small round blue cell tumors and DlBCl has not yet become routine clinical practice. second, it is necessary to validate these tests to prove their clinical utility. the requirement for large-scale, cross-institutional studies that are difficult and expensive to conduct, is a potential problem for the widespread adoption of these tests. nevertheless, it is encouraging that the KRAS test was widely adopted without the need for FDa approval. third, clinicians will need guidance about which tests are required to examine tumors for their mutations, and what consequences the results will have with respect to treatment and follow-up. this issue is more complicated than, but analogous to, blood test results that are currently requested and acted on in cardiovascular and other diseases. the bioinformatics needed to provide digested and useful information to the clinician to guide the decision-making process is not trivial. educating clinicians to appreciate molecular profiling will be important, because it will be a clear economic driver for health in the future. the same amount of effort is needed for planning Box 3 | Genetic risk assessment for disease prevention There is increasing commercial interest in providing so-called relative genetic risk information to individuals derived from genome-wide association studies. Several companies, including Navigenics (Foster City, CA, USA), deCODEme (Reykjavik, Iceland) and 23andMe (Mountain view, CA, USA) provide this information in the context of lifestyle management and wellness programs to enable people to prospectively ameliorate their genetic predisposition. The clinical utility of single, common low-penetrance gene information is limited, but for breast cancer for example, there are some susceptibility alleles that may distinguish women who are at high risk of breast cancer from those at low risk, particularly in the context of population screening. 163 The Scripps Clinic genomics group has announced a screening initiative of 3,500 individuals to identify the common single nucleotide polymorphisms that predispose women who have had at least five years of mammography, to breast cancer. 164 Given the influence of environment on the outcome of an individual's genetic predisposition, however, currently available genetic predisposition information obtained from direct DNA sequencing, or by genome-wide association studies is not going to be very accurate. 18, 165, 166 Even highly penetrant gene mutations, such as the deletion mutation in position 508 of the cystic fibrosis transmembrane conductance regulator gene give rise to widely different phenotypes, which is reflected in the severity of the resultant cystic fibrosis, little of which is accounted for by other genetic effects. Humans are also generally incapable of dealing with the concept of relative risk; whether relative genetic risk will be taken more seriously by an increasingly socially networked population remains to be seen. The cost of the delivery and the utility of this type of genetic information ($2,500-$4,000), however, need to be put into perspective, given that the cost of a BRCA1 test is similar and yields more actionable information.
how to provide the molecular information content to electronic health records as planning how to develop and deliver the electronic health records themselves. 152, 153 the speed by which information can be derived from initial patient presentation to diagnosis, will be important in the future and increase the pathologist's role in active diagnosis, leading to a need for more interventional molecular pathologists. For example, EGFR mutations in nsClC is important for the patients in real time, since EGFR inhibitors are effective in these patients, at least until resistance emerges. 154 the stakeholders, which include the payers, health care organizations, pharmaceutical and biotechnology industry, and molecular diagnostics companies, need to be aligned to achieve the most effective partnership. the delivery of molecular diagnostics for therapy poses several challenges, including the complexity of the data and the operational delivery of the tests; however, by far the most important challenge is to align the stakeholders economically. 155 ensuring that there are incentives for the payers to provide financial support for diagnostic tests with longterm consequences, is an issue. additionally, reimbursement practice must be in line with the utility of the drug for a subset of patients; for example, no re imbursement should be given for EGFR-targeted drugs unless they are accompanied by a KRAS wild-type desig nation for the patient. the intellectual property issues could also be considerable when the changes in several genes need to be measured at the same time to allow accurate patient profiling for optimal drug treatment and follow-up. somatic mutation analysis of tumors can make a dramatic difference to the economic fate of the patient. the KRAS mutation test costs $400 for an $80,000 decision, which could save $20 million for every 1,000 metastatic colon cancer patients who progress to second-line therapy directed at EGFR inhibition, saving approximately $600 million per year. using the oncotype DX ® test to avoid unnecessary chemotherapy could also save approximately $2,000 per patient based on a 34% reduction in the use of chemotherapy.
Given the short-term pressures on maintenance of shareholder value for large biotechnology and pharma ceutical companies, encouraging them to take a long-term view without incentives is not feasible. the pharmaceutical and biotechnology industry has to accept the fact that the patient population who respond well to treatment might be <20% of the total patients with that particular disease, thus apparently reducing their potential market by 80%. the current economic climate means that the very expensive cancer drug treatments that sometimes only increase survival by a few weeks, have to be used selectively in patients whose molecular profile indicate efficacy. the pricing of small-molecule tyrosine kinase inhibitors based on the price of a drug that is efficacious in the majority of patients, such as imatinib in Cml, is completely unjustified unless the drugs have the same efficacy profile in the overall patient populations in which they are used; most of them do not. However, as patients who are treated with a targeted therapy would be expected to live longer and therefore need the drugs for longer, the economics of targeted therapy may be better than expected for the pharmaceutical companies. the use of EGFR inhibitors in profiled stage iv lung cancer patients with EGFR mutations can give striking increases in survival from the 18-week average to 2-3 years. From an economic perspective, the experience and success of imatinib as a targeted therapeutic definitively supports the view that patient stratification is in the best interests of the drug companies economically.
Cancer is most likely to be the disease where the full adoption of personalized medicine takes place. the rapid analysis of mutations in all cancers found by using new Dna sequencing techniques will be the catalyst for this change.
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